Matritech deal

NMPS granted an option to Bayer Corp.'s diagnostics division (Tarrytown, N.Y.) to develop cervical cancer detection systems based on NMPS's Nuclear Matrix Protein (NMP) technology. If the option is exercised, Bayer will receive worldwide rights to sell automated NMP-based cervical cancer systems using raw materials supplied by NMPS. The tests will use the Cambridge, Mass., company's antibodies, which detect cervical cancer-specific Nuclear Matrix Proteins. ...